155 related articles for article (PubMed ID: 23404469)
21. Effect of nimesulide on the growth of human laryngeal squamous cell carcinoma.
Liang Z; Liu J; Li L; Wang H; Zhao C; Jiang L; Qin G
Am J Otolaryngol; 2014; 35(2):120-9. PubMed ID: 24321753
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
[TBL] [Abstract][Full Text] [Related]
23. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer.
Liu T; Zhang M; Zhang H; Sun C; Yang X; Deng Y; Ji W
Eur J Pharmacol; 2008 Jun; 587(1-3):78-84. PubMed ID: 18442812
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Premkumar DR; Jane EP; Pollack IF
Int J Oncol; 2010 Sep; 37(3):633-43. PubMed ID: 20664932
[TBL] [Abstract][Full Text] [Related]
25. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
26. Initial testing of dasatinib by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
[TBL] [Abstract][Full Text] [Related]
27. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
[TBL] [Abstract][Full Text] [Related]
28. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
[TBL] [Abstract][Full Text] [Related]
29. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
[TBL] [Abstract][Full Text] [Related]
30. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
31. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
Finn RS; Aleshin A; Dering J; Yang P; Ginther C; Desai A; Zhao D; von Euw E; Busuttil RW; Slamon DJ
Hepatology; 2013 May; 57(5):1838-46. PubMed ID: 23299860
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
33. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
[TBL] [Abstract][Full Text] [Related]
34. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
Scott AJ; Song EK; Bagby S; Purkey A; McCarter M; Gajdos C; Quackenbush KS; Cross B; Pitts TM; Tan AC; Eckhardt SG; Fenton H; Arcaroli J; Messersmith WA
PLoS One; 2017; 12(11):e0187173. PubMed ID: 29091939
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
38. [In vitro inhibition of human laryngeal squamous cell carcinoma cell line by 1,25(OH)2D3].
Cai P; Wu Z; Li J
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Jun; 20(12):538-40, 544. PubMed ID: 16941961
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib induces autophagic cell death in human ovarian cancer.
Le XF; Mao W; Lu Z; Carter BZ; Bast RC
Cancer; 2010 Nov; 116(21):4980-90. PubMed ID: 20629079
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]